Related Experiment Video
Updated: Aug 27, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
[Postoperative Recurrent Lung Cancer Successfully Treated with Alternate Day Administration of Gefitinib]
Takato Onda1, Hidefumi Kita, Tsutomu Yoshida
1Department of Thoracic Surgery, Tokorozawa Chuo Hospital, Tokorozawa, Japan.
Abstract:
A 57-year-old man was referred to our department for further examination for chest abnormal shadow in the right upper lobe. Positron emission tomography (PET)-computed tomography (CT) showed abnormal accumulation of fluorodeoxyglucose (FDG). Because of lung cancer could not be denied, he underwent right upper lobectomy and the nodule was diagnosed as adenocarcinoma by pathology. A chest CT performed one and a half years after surgery showed multiple lung nodules and was diagnosed as recurrence. Since the deletion mutation of exon19 was confirmed in the epidermal growth factor receptor( EGFR) gene mutation analysis, gefitinib( 250 mg/day) daily administration was started. Multiple lung nodules were almost banished promptly, but severe skin rash developed, so gefitinib administration was reduced to 250 mg/every second day and the skin rush disappeared. In spite of reduced dose antitumor effect was maintained for two years without recurrence of skin rash.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016